Treat to target in Gout
What is the clinical and cost-effectiveness of using a goal-directed allopurinol-based treat-to-target protocol in people with recurrent gout flares? Protocol for a randomised controlled trial and internal pilot study.
The objectives of this study are to evaluate the effects of allopurinol-based treat-to-target ULT on the number of gout attacks (primary outcome), gout flare severity, serum urate, quality of life, renal function and adverse events. We will also examine the cost-effectiveness, acceptability and adherence to such treatment.
Professor Abhishek Abhishek (University of Nottingham)
|Associate Investigator:||Professor Edward Roddy|
|Sponsor / reference number:||Keele University|
|Funder / reference number:||NIHR HTA / 17/82/02|
|Registration reference number:||ISRCTN12059648|
|Start date:||1 Jan 2019|
|End date:||1 Aug 2025|
Parallel-arm multicentre randomised controlled trial with one-year internal pilot and a two-year long-term extension phase.
Aim and objectives
To evaluate the long-term effect of continued allopurinol-based treat-to-target ULT versus usual GP care on number of gout flares in years 3-4.
To evaluate the long-term effect of continued allopurinol-based treat-to-target ULT versus usual GP care on healthcare utilisation for gout in years 3-4, incidence of comorbidities, and mortality.